The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aegerion.com

Founded Year

2005

Stage

Asset Sale | AssetsPurchased

Total Raised

$40.11M

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a specialty pharmaceutical company. The company is focused on the development and commercialization of pharmaceuticals to treat cardiovascular and metabolic disease.

Aegerion Pharmaceuticals Headquarter Location

1 Main St Suite 800

Cambridge, Massachusetts, 02142,

United States

617-945-7968

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aegerion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aegerion Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aegerion Pharmaceuticals Patents

Aegerion Pharmaceuticals has filed 10 patents.

The 3 most popular patent topics include:

  • Syndromes
  • Diabetes
  • Diseases of liver
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/12/2017

9/15/2020

G protein coupled receptors, Peptide hormones, Syndromes, Rare diseases, Obesity

Grant

Application Date

9/12/2017

Grant Date

9/15/2020

Title

Related Topics

G protein coupled receptors, Peptide hormones, Syndromes, Rare diseases, Obesity

Status

Grant

Latest Aegerion Pharmaceuticals News

Amryt Announces Details of EMA Contingent Value Rights Payment

May 17, 2022

Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that, following the CHMP positive opinion for Filsuvez® on April 22, 2022, the European Medicines Agency (EMA) Contingent Value Rights (“CVRs”) issued to those Amryt shareholders and option holders who held Amryt shares or options prior to the acquisition of Aegerion Pharmaceuticals, Inc. (“CVR Holders”) will now become payable. The total amount payable to CVR Holders will be approximately USD$5.7million. Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a “Loan Note”). The certificates for the Loan Notes will be held by the Company’s Registrar, Link Group (“Link”), in electronic form on behalf of each CVR Holder. The Loan Notes will be redeemed in full on September 14, 2022 (the “Payment Date”) in accordance with the terms and conditions of the CVR Deed Poll and the Deed Poll constituting the Loan Notes (the form of which was appended to the CVR Deed Poll), which was executed by the Company on May 3, 2022. The total amount due to each CVR Holder will be paid by cheque on the Payment Date. Further information relating to Amryt’s CVR’s can be found on the Amryt website:       About Amryt  Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt’s commercial business comprises three orphan disease products – metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); and lomitapide (Juxtapid®/ Lojuxta®). Myalept®/Myalepta® (metreleptin) is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this  link . Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approved by the FDA. Mycapssa® has also been submitted to the EMA and is not yet approved in Europe. For additional information, please follow this  link . Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal productsfor adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel, Saudi Arabia and Brazil (under the trade name Lojuxta®). For additional information, please follow this  link. Amryt's lead development candidate, Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Filsuvez® has been selected as the brand name for Oleogel-S10. Filsuvez® received a positive CHMP opinion on April 22, 2022 for the treatment of partial thickness wounds associated with Dystrophic and Junctional EB in patients 6 months and older in the European Union (EU). The product does not currently have regulatory approval to treat EB. Amryt’s pre-clinical gene therapy candidate, AP103, offers a potential treatment for patients with Dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders. Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE®) technology platform. For more information on Amryt, including products, please visit  www.amrytpharma.com . Forward-Looking Statements This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management. Contacts Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,  tim@lifesciadvisors.com

  • When was Aegerion Pharmaceuticals founded?

    Aegerion Pharmaceuticals was founded in 2005.

  • Where is Aegerion Pharmaceuticals's headquarters?

    Aegerion Pharmaceuticals's headquarters is located at 1 Main St, Cambridge.

  • What is Aegerion Pharmaceuticals's latest funding round?

    Aegerion Pharmaceuticals's latest funding round is Asset Sale.

  • How much did Aegerion Pharmaceuticals raise?

    Aegerion Pharmaceuticals raised a total of $40.11M.

  • Who are the investors of Aegerion Pharmaceuticals?

    Investors of Aegerion Pharmaceuticals include Amryt, Novelion Therapeutics, Medicxi Ventures, Advent International, MVM Partners and 5 more.

  • Who are Aegerion Pharmaceuticals's competitors?

    Competitors of Aegerion Pharmaceuticals include EUSA Pharma, Cornerstone Pharmaceuticals, Bellus Health, Xhale, Viamet Pharmaceuticals, Athenex, AkaRx, Salix Pharmaceuticals, Hyperion Therapeutics, Radius Health and 31 more.

You May Also Like

E
ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

D
Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

P
Pet Medicus Laboratories

Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.

V
Verva Pharmaceuticals

Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.